뇌종양 치료제 시장 : 치료 유형, 적응증, 유통 채널별 - 세계 전망(2025-2030년)

The Brain Cancer Drugs Market was valued at USD 2.03 billion in 2023, expected to reach USD 2.18 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 3.35 billion by 2030.

The scope of the market for brain cancer drugs encompasses the development, production, and distribution of therapeutic agents specifically targeting brain tumors. These include chemotherapy, targeted therapies, immunotherapy, and supportive care drugs aimed at treating different types of brain cancers like glioblastomas, astrocytomas, and oligodendrogliomas. The necessity for such drugs is driven by the increasing incidence of brain cancer, which requires innovative treatments that can penetrate the blood-brain barrier and offer improved efficacy with fewer side effects. The application of these drugs is mainly in hospitals, clinics, and specialized cancer treatment centers, with end-users consisting of medical professionals and patients requiring tailored cancer treatment plans.

Market growth is influenced by key factors such as advancements in medical technology, increased research funding, and rising awareness of early cancer detection. The emergence of personalized medicine and next-generation sequencing technologies provide significant opportunities for developing targeted therapies, offering growth potential. Currently, collaborations between pharmaceutical companies and research institutions are opening doors for innovative drug discovery and clinical trials. A major recommendation to capitalize on these opportunities includes investing in R&D for drugs focusing on the genetic and molecular profiling of tumors, which can enable more precise targeting and improved patient outcomes.

However, the market also faces limitations from high developmental and approval costs, stringent regulatory requirements, and challenges in effectively crossing the blood-brain barrier. Another significant challenge is the aggressive nature of some brain tumors, which often leads to high relapse rates and resistance to conventional therapies. Areas ripe for innovation include the development of drugs that can effectively target tumor vasculature and microenvironment, and novel delivery systems such as nanoparticles to enhance drug delivery to the brain. The market's nature is highly dynamic and competitive, necessitating continuous innovation and adaptation by stakeholders to meet unmet patient needs and overcome existing market constraints.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Drugs Market

The Brain Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of brain cancer with sedentary lifestyles
  • Surge in geriatric population suffering from neurological disorders
  • Rising patient awareness on the availability of treatment
• Market Restraints
  • Use of targeted therapies to block cancer growth
• Market Opportunities
  • Favorable initiatives from government and pharmaceutical companies in the development of the drug
  • Robust development in areas such as use of nanoparticles to carry drugs
• Market Challenges
  • Strict regulatory guidelines in the approval of these drugs

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Drugs Market

A detailed market share analysis in the Brain Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Drugs Market

A strategic analysis of the Brain Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Antisense Therapeutics Limited, Aravive, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, Dr. Reddy's Laboratories, Elevar Therapeutics, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi, Ltd., Johnson & Johnson Services Inc., Koninklijke Philips N.V., Leadiant Biosciences, Inc., Mankind Pharma Pvt. Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy.
• Based on Indication, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors.
• Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of brain cancer with sedentary lifestyles
    • 5.1.1.2. Surge in geriatric population suffering from neurological disorders
    • 5.1.1.3. Rising patient awareness on the availability of treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Use of targeted therapies to block cancer growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable initiatives from government and pharmaceutical companies in the development of the drug
    • 5.1.3.2. Robust development in areas such as use of nanoparticles to carry drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory guidelines in the approval of these drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Brain Cancer Drugs Market, by Therapy Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Targeted Therapy

7. Brain Cancer Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Glioblastoma
• 7.3. Meningioma
• 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Retail pharmacy

9. Americas Brain Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Brain Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Antisense Therapeutics Limited
• 2. Aravive, Inc.
• 3. AstraZeneca PLC
• 4. Bristol Myers Squibb Company
• 5. Dr. Reddy's Laboratories
• 6. Elevar Therapeutics, Inc.
• 7. F. Hoffmann-La Roche AG
• 8. Fujifilm Corporation
• 9. GE Healthcare
• 10. Hitachi, Ltd.
• 11. Johnson & Johnson Services Inc.
• 12. Koninklijke Philips N.V.
• 13. Leadiant Biosciences, Inc.
• 14. Mankind Pharma Pvt. Ltd.
• 15. Merck & Co., Inc.
• 16. Novartis International AG
• 17. Pfizer, Inc.
• 18. Siemens Healthineers AG
• 19. Thermo Fisher Scientific, Inc.